Antinuclear antibodies in primary pulmonary hypertension  by Rich, Stuart et al.
lACC Vol. 8, No.6
December 1986:1307-11
Antinuclear Antibodies in Primary Pulmonary Hypertension
1307
STUART RICH MD, FACC,* KAREN KIERAS, RN,* KIM HART, RN,*
BERTRON M. GROVES, MD, FACC,t JOHN D. STOBO, MD,:j: BRUCE H. BRUNDAGE, MD, FACC*
Chicago, Illinois, San Francisco, California, Denver, Colorado
The association of positive antinuclear antibodies with
the clinical and hemodynamic features of 43 patients
with primary pulmonary hypertension and 16 patients
with secondary pulmonary hypertension was investi-
gated. Each patient had determinations of antinuclear
antibodies using a KB cell substrate immunofluorescent
test. Of the patients with primary pulmonary hyperten-
sion, 40% had positive antinuclear antibodies at titers
of 1:80 dilutions or greater. There were no differences
between patients with primary pulmonary hypertension
and positiveantinuclear antibodies compared with those
with negative antinuclear antibodies in relation to clin-
ical or hemodynamic status. A 6% incidence rate of
antinuclear antibodies was found in patients with sec-
ondary pulmonary hypertension, similar to that in the
normal population.
Primary pulmonary hypertension has been associated with
autoimmune phenomena in previously reported studies (I).
The meaning of this association is unclear, but because of
the occurrence of pulmonary hypertension in the collagen
vascular diseases it has been speculated that there may be
a link between primary pulmonary hypertension and col-
lagen vascular or autoimmune disorders (2,3). We inves-
tigated this relation by evaluating the frequency and titer of
antinuclear antibodies in patients with both primary and
secondary pulmonary hypertension.
Methods
Study patients. The study group consists of 43 patients
referred to the University of Illinois at Chicago, University
of California in San Francisco and University of Colorado
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The clinical, hemodynamic, serologic and histologic
similarity betweenpatients with primary pulmonary hy-
pertension and those with unexplained pulmonary hy-
pertension associated with collagen vascular disorders
suggests that primary pulmonary hypertension in some
patients may represent a collagen vascular disease con-
fined to the lungs. The frequency of positiveantinuclear
antibody tests would place primary pulmonary hyper-
tension between rheumatoid arthritis and scleroderma
in the spectrum of collagen vascular diseases. Further
studies are necessary, however, before one might expect
that immunosuppressive therapy would be beneficial to
these patients.
(J Am Coll Cardiol 1986;8:1307-11)
with primary pulmonary hypertension, as well as 16 patients
from the former two universities with secondary pulmonary
hypertension. All patients sought medical attention because
of clinical symptoms related to their disease. Each patient
underwent an extensive evaluation to search for any sec-
ondary cause of pulmonary hypertension (4). Patients were
also screened for recent therapy with drugs known to cause
positive antinuclear antibody (ANA) tests, and underwent
thorough clinical examinations for eye, skin, joint or other
organ system findings that might suggest the presence of
any type of collagen vascular disorder.
Patient characterization. Patients were classified from
their history according to functional capacity by the New
York Heart Association classification system, and the du-
ration of their disease was estimated as the period between
the time that the patient first noted symptoms that could be
attributed to pulmonary hypertension until the current eval-
uation. Patients who had no identifiable cause for pulmonary
hypertension were classified as having primary pulmonary
hypertension. Those with congenital or acquired heart dis-
ease or lung disease were classified as having secondary
pulmonary hypertension, even if the degree of the pulmo-
nary hypertension seemed out of proportion to their under-
lying disease state.
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Hemodynamic evaluation. Baseline hemodynamic val-
ues were determined with the patients at rest, supine, after
an overnight fast while receiving no cardiac medications
other than digoxin and diuretic agents. A thermodilution
flow-directed catheter was introduced into the pulmonary
artery, and a short Teflon cannula was placed into a radial
or femoral artery. Pressures were recorded on a multichannel
recorder with mean pressures determined by electronic in-
tegration. Cardiac output was taken as the average of three
serial determinations using a thertnodilution computer. The
calculation of systemic and pulmonary vascular resistance
(in Wood units) was according to conventional formulas.
Antinuclear antibody determinations. Two sets of an-
tinuclear antibody determinations were performed on each
patient, with their informed consent. One was through the
conventional hospital laboratory for the respective hospital,
and employed indirect fluorescent antibody testing using the
Hep2 cell line at the University of Illinois, Swiss-Webster
mouse kidney cell at the University of Colorado and KB
cell line at the University of California. In addition, each
sample was tested again in the University of Illinois research
laboratory for antinuclear antibody with an indirect flu-
orescent antibody test utilizing the human KB cell line (Elec-
tro-Nucleonics, Inc.). Peripheral blood serum samples were
either analyzed immediately, or frozen at - 20°C and ana-
lyzed at a later date. Each serum was diluted 1: 10, followed
by doubling dilutions up to 1: 1,280. Goat antihuman
immunoglobulinG conjugated with fluorescein isothiocyan-
ate (Electro-Nucleonics, Inc.) was used as the second an-
tibody. The slides were provided with a cover glass using
phosphate-buffered glycerol (pH 8.0) and read on a Nikon
epifluorescent microscope with standard fluorescein filters
and a fluorite 40 x objective. A positive test was determined
by the presence of nuclear fluorescence at a dilution of I :20
or greater. The end point for the titer was the highest dilution
showing a 1+ intensity. Samples that showed a positive
reaction at I :20 were then titered for the end point of reac-
tivity. The staining pattern was also noted, and subcate-
gorized as homogeneous, peripheral, speckled or nucleolar.
Internal controls from sera with known positive and negative
antinuclear antibodies were established before the testing of
each group of samples.
Control population. To reestablish the frequency of
elevated titers in a presumed normal population, serum sam-
ples were obtained from 20 university employees who were
healthy and taking no medications. These specimens were
tested on two separate occasions for antinuclear antibody
using the KB cell substrate. Our normal control subjects
had the following results: negative, II subjects; positive
(l : 20), 5 subjects; positive (l :40), 4 subjects and positive
(> 1:40), no subjects.
Statistical methods. The mean and standard deviation
for variables in patients with and without a positive anti-
nuclear antibody test were computed, and differences be-
Table 1. Patients With Primary Pulmonary Hypertension and a Positive Antinuclear
Antibody Test
Age (yr) NYHA Duration PAP PVR ANA
Case &Sex Class (yr) (mmHg) (units) Titer Type
I 28F 11 2.0 41 7 1280 S
2 22F 11 0.5 35 5.7 1280 P
3 20F 11 1.5 77 29 1280 P
4 45M IV 7.0 67 22.9 1280 P
5 27F I1I 4.0 65 47.7 1280 S
6 IIF I1I 0.6 83 38.7 640 S
7 59F I1I 4.0 71 7.9 640 S
8 53F IV 2.0 63 44.0 640 S
9 35F I1I 2.6 78 23.9 640 S
10 52F I1I 4.0 62 13.6 320 S
11 60F I1I 5.0 58 11.6 320 S
12 40F IV 1.5 50 19.2 320 S
13 55M 11 0.2 65 12.6 160 S
14 55F I1I 8.0 55 14.4 80 H
15 20F IV 1.0 49 10.3 80 H
16 22F I1I 0.6 42 12.3 80 P
17 42M 11 5.0 48 13.8 80 S
Mean (n = 8) 38 2.9 2.9 59.3 19.7
±SD 16 0.7 2.3 13.9 13
ANA = antinuclear antibody; F = female; H = homogeneous; M = male; NYHA class = New York
Heart Association functional class; P = peripheral; PAP = mean pulmonary artery pressure; PVR = pulmonary
vascular resistance; S = speckled.
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tween them were evaluated by use of the Student's t test
for unpaired data. Significance was taken to be at a prob-
ability of less than 5% (p < 0.05).
Results
It has been shown that the titer that one uses to categorize
patients with a positive antinuclear antibody test will in part
determine the sensitivity and specificity ofthe test (5). Based
on the results of our normal control subjects we classified
patients with primary pulmonary hypertension as having a
positive antinuclear antibody test if they had a titer of I :80
or greater with the KB cell substrate.
Antinuclear antibodies in primary pulmonary hyper-
tension with titers of 1:80 or greater. The demographic,
hemodynamic and antinuclear antibody results of testing
with the KB cell line in patients with primary pulmonary
hypertension is listed in Table I. Of the 43 patients with
primary pulmonary hypertension tested, 17 (40%) had an
antinuclear antibody titer of 1:80 or greater. Of the 17 with
positive antinuclear antibodies, 14 were women and 3 were
men versus 18 women and 8 men with negative antinuclear
Table 2. Patients With Primary Pulmonary Hypertension and
Negative Antinuclear Antibody Test
Age (yr) NYHA Duration PAP
Case &Sex Class (yr) (mm Hg) PYR
18 41F 4 7.0 47 19.2
19 55F 4 0.3 74 19.7
20 26F 3 9.0 61 17.8
21 51F 3 5.0 65 13.1
22 39M 2 2.0 57 14.5
23 17F 4 1.5 79 15.9
24 21M 4 0.5 127 34.8
25 34F 3 7.0 54 19.1
26 61F 4 2.8 73 25.4
27 33M 3 5.4 50 14.0
28 22F 2 9.0 56 11.2
29 38F 3 7.0 41 13.7
30 31F 2 10.0 62 20.6
31 40M 2 1.5 49 3.5
32 33F 2 2.5 42 8.8
33 50M 2 8.0 55 9.0
34 25F 4 0.2 43 17.5
35 30F 4 2.3 68 33.5
36 57M 3 2.0 40 11.7
37 25F 4 0.4 68 17.4
38 19F 2 6.0 73 21.0
39 13F 3 0.8 46 13.3
40 11M 2 2.0 115 38.6
41 44F 3 0.7 60 23.0
42 33M 3 2.0 70 23.0
43 38F 2 1.8 77 16.7
Mean 32.8 3.0 3.7 63.5 18.3
±SD 13.0 0.8 3.2 20.7 8.1
Abbreviations as in Table I.
antibodies (Table 2). The mean age for all patients was
39 ± 15 years with similar ages for those with positive and
negative antinuclear antibodies. Functional class based on
the New York Heart Association classification averaged
3.0 ± 0.7 with no difference between those with a positive
and those with a negative antinuclear antibody test. In ad-
dition, the duration of the disease as determined by the onset
of symptoms attributable to pulmonary hypertension was
3.6 ± 3 years, and was similar for both subgroups. Two
of 17 patients with a positive antinuclear antibody test and
3 of 25 with a negative test had a history of Raynaud's
phenomenon. At the time of the rest hemodynamic mea-
surements, all of the patients had severe pulmonary hyper-
tension as manifested by extremely high mean pulmonary
artery pressure (mean 59 ± 18 mm Hg) and pulmonary
vascular resistance (mean 19 ± 7 Wood units). There was
no significant difference in the pulmonary artery pressure,
cardiac output or pulmonary vascular resistance of the pa-
tients with a positive as opposed to those with negative
antinuclear antibody test.
Staining patterns of antinuclear antibodies. The stain-
ing pattern of the patients with a positive antinuclear anti-
body test with the KB cell substrate was studied. In the
patients with primary pulmonary hypertension the staining
pattern was speckled in II, peripheral in 4 and homogeneous
in 2. There were no significant clinical or hemodynamic
differences among patients based on the staining pattern of
the antinuclear antibody.
Relative sensitivity of different antinuclear antibody
tests. The sensitivity of the KB antinuclear antibody test
was compared with the Hep2 test utilized at the University
of Illinois, and the mouse kidney test utilized at the Uni-
versity of Colorado in those patients who were tested with
both (Table 3). Six of the 11 patients with a positive KB
test had a positive titer at I: 80 or greater dilutions on the
Table 3. Results Using Different Antinuclear
Antibody Tests in Patients With Primary
Pulmonary Hypertension and a Positive
Antinuclear Antibody Test
Titer
KB (n = 20) Hep2
1:20 3 0
1:40 6 2
1:80 I 0
I: 160 0 I
I: 160 10 5
KB (n = 4) Mouse Kidney
1:20 0 I
1:40 2 0
1:80 2 0
I: 160 0 0
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Table 4. Patients With Secondary Pulmonary Hypertension
Age (yr) PAP ANA
Case & Sex Diagnosis (mmHg) Titer Type
44 28F ASD 60 Neg
45 32F ASD 95 Neg
46 30M YSDrrGA 73 Neg
47 19M AS/AI 52 Neg
48 29F TGA 45 Neg
49 36F ASD 85 Neg
50 66F PE 38 Neg
51 62F ILD 32 Neg
52 34M PDA 69 160 S
53 46F PE 59 Neg
54 59F MS 73 40 S
55 23M YSD 80 Neg
56 37F YSD 54 40 S
57 40M MS 59 Neg
58 61M MS 59 40 S
59 49M PE 60 40 S
ASD = atrial septa) defect; AS/AI = aortic stenosis/aortic insufficiency; ILD = interstitial lung disease:
MS = mitral stenosis; Neg = negative; PDA = patent ductus arteriosus; PE = pulmonary emboli; TGA =
transposition of the great arteries; YSD = ventricular septal defect; other abbreviations as in Table I.
Hep2 line. None of the two patients with a positive KB test
from the University of Colorado had a positive antinuclear
antibody test using the mouse kidney cell substrate. Spec-
imens from the University of California were tested twice
with a KB test. The percent of positive tests was identical,
and the titer never differed by more than one dilution be-
tween the two tests.
Secondary pulmonary hypertension. To examine
whether a positive antinuclear antibody test in a patient with
primary pulmonary hypertension is a manifestation of the
disease as opposed to a phenomenon related to the presence
of an elevated pulmonary artery pressure. (for example.
endothelial damage with exposure of "new antigens"), we
obtained sera from 16patients with pulmonary hypertension
of similar magnitude secondary to other causes and evalu-
ated the presence of antinuclear antibodies using the KB
cell test. Table 4 describes these 16 patients, 8 of whom
had pulmonary hypertension secondary to congenital heart
disease. and 8 of whom had pulmonary hypertension sec-
ondary to adult acquired heart or lung disease. Only one
patient had a titer of greater than I :40 (Patient 52). Although
we have classified this patient as having pulmonary hyper-
tension secondary to congenital heart disease. he had a pat-
ent ductus arteriosus closed during infancy and developed
the pulmonary hypertension in adult life, which raises a
question as to whether the development of the pulmonary
hypertension was perhaps primary in nature.
Discussion
Prevalence and significance of positive test for anti-
nuclear antibodies. Although an association between anti-
nuclear antibodies and primary pulmonary hypertension has
been previously made, no prior study has determined the
frequency of positive antinuclear antibody tests with this
disease. We found a positive antinuclear antibody test in
40% of cases using a KB cell substrate and using a titer of
I :80 or greater to determine positivity. Had the prevalence
in our group been based on standard antinuclear antibody
tests performed at the respective hospitals, patients tested
at the University of Illinois would have had only 23% pos-
Figure 1. Relative frequency of positive (I : 80) antinuclear an-
tibody titers in various collagen vascular diseases using the KB
cell substrate. Data from patients with collagen vascular disease
come from sera of 100 patients at the University of Texas (6).
Data for primary pulmonary hypertension (PPH) come from the
43 patients in this study . Primary pulmonary hypertension appears
to fall between rheumatoid arthritis (RA) and scleroderma (sys-
temic sclerosis [SS]) with respect to the frequencyof positive tests.
OLE = discoid lupus erythematosus; OM-PM = dermatomyo-
sitis-polymyositis; NL = normal subjects; SLE = systemic lupus
erythematosus.
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itive tests (versus our result of 37%), and those at the Uni-
versity of Colorado would have had no positive tests (versus
our result of 40%). This probably accounts for the varying
frequencies in the association between positive antinuclear
antibodies and primary pulmonary hypertension in the past.
The KB cell substrate is perhaps the most sensitive test for
antinuclear antibodies. One study (5) showed that a large
number of patients who were originally categorized as hav-
ing "seronegative" lupus were "seropositive" when re-
tested on the KB cell line. The specificity of the KB anti-
nuclear antibody test obviously depends on the titer that one
uses to define a positive test. At titers of I : 160 or greater,
less than 5% of the normal population will have a positive
test (6). At titers of I :20 or greater this rises to 23%.
Consequently, low titer positive antinuclear antibody results
are often considered nonspecific.
We defined a positive antinuclear antibody test as a titer
that was I: 80 or greater, based on our own control group.
There was no way to distinguish on clinical grounds patients
with primary pulmonary hypertension who had a positive
antinuclear antibody test from those who did not. We saw
no difference between them with respect to sex, age, func-
tional class, duration of symptoms or hemodynamic status,
nor did there appear to be any difference in their clinical
course or survival. Even with exclusion of the four patients
whose positivity was borderline (1 :80), the prevalence rate
is 30%, still much higher than that expected from a normal
population. When these four patients are classified as having
a "negative" antinuclear antibody test, there is no signif-
icant difference between the groups with a positive and a
negative antinuclear antibody test.
Primary pulmonary hypertension as a collagen vas-
cular disease. The increased prevalence of antinuclear an-
tibodies in patients with primary pulmonary hypertension
raises the possibility that the etiologic basis of primary pul-
monary hypertension in some patients may be an autoim-
mune mechanism. Pathologic specimens of patients with
primary pulmonary hypertension and pulmonary hyperten-
sion secondary to collagen vascular disease show very sim-
ilar patterns. A review of the published data (2,3,7,8) on
pulmonary vascular hypertension in patients with collagen
vascular disease examined for lung disease consistently doc-
uments plexogenic arteriopathy indistinguishable from pri-
mary pulmonary hypertension with the absence of active
vasculitis. The point has been made repeatedly from these
studies that primary pulmonary hypertension and pulmonary
hypertension in patients with collagen vascular disease with-
out interstitial lung disease appear identical histologically.
If primary pulmonary hypertension is a collagen vascular
disorder in some patients, it might be placed between rheu-
matoid arthritis and scleroderma with regard to the fre-
quency of positive antinuclear antibody tests found (Fig. I).
The prevalence of the speckled pattern in both the primary
and secondary group is of interest, but it is difficult to
speculate on the clinical significance, because speckled pat-
terns appear to be the most common patterns seen in all
collagen vascular diseases.
The 6% incidence rate of antinuclear antibodies in pa-
tients with secondary pulmonary hypertension may be a
nonspecific finding, because it is similar to that of the normal
population. This would support the view that a positive
antinuclear antibody test of I: 80 dilutions or greater in
patients with primary pulmonary hypertension is neither
nonspecific nor secondary to elevated pulmonary artery
pressures, but rather a feature of the disease state itself.
Therapeutic implications. The implications of the pres-
ence of antinuclear antibodies in patients with primary pul-
monary hypertension with regard to therapy must be ad-
dressed. Unfortunately, it is often difficult to show significant
benefits of immunosuppressive therapy in patients with overt
collagen vascular disorders. However, case reports (9,10)
have appeared describing patients with pulmonary hyper-
tension secondary to collagen vascular disease whose hy-
pertensive state appears to be ameliorated somewhat with
treatment by steroids and irnmunosuppressives. At present
it is premature to recommend immunosuppressive therapy
for primary pulmonary hypertension but clearly all feasible
avenues of treating these patients need to be explored.
We are grateful to Electro-Nucleonics, Inc., for supplying the KB anti-
nuclear antibody testing kits, and to Mary F. Lipscomb, MD and David
Hellmann, MD for helpful comments regarding this study.
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